Clinical Trial Update: A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 study of JCXH-105, an srRNA-based vaccine for herpes zoster (shingles), has completed its Phase 1 evaluation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• JCXH-105

Snippet

Sponsor: Immorna Biotherapeutics, Inc. | Conditions: Herpes Zoster (HZ), Shingles | Phase 1 | Status: COMPLETED